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The aim of this study was to investigate the relationship between urinary eosinophil protein X (uEPX) and asthma symptoms, lung
function, and other markers of eosinophilic airway inflammation in asthmatic school children. Methods. A cross-sectional study
was performed in 180 steroid dependent atopic children with stable moderately severe asthma, who were stable on 200 or 500μg
of fluticasone per day. uEPX was measured in a single sample of urine and was normalized for creatinine concentration (uEPX/c).
Symptom scores were kept on a diary card. FEV1 and PD20 methacholine were measured. Sputum induction was performed in
49 and FENO levels measured in 24 children. Results. We found an inverse correlation between uEPX/c and FEV1 (r = −.20,
P = .01) and a borderline significant correlation between uEPX/c and PD20 methacholine (r = −.15, P = .06). Symptom score,
%eosinophils and ECP in induced sputum and FENO levels did not correlate with uEPX/c. Conclusion. uEPX/c levels did not
correlate with established markers of asthma severity and eosinophilic airway inflammation in atopic asthmatic children.
Copyright © 2007 M. Nuijsink et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Eosinophilic airway inflammation is the pathological sub-
strate of allergic asthma both in adults and in children [1, 2].
The severity of airway inflammation correlates poorly with
symptoms and lung function [3]. As asthma treatment with
inhaled steroids aims at reducing inflammation, there is a
need to monitor the disease with a marker of inflammation
[4, 5]. Potential markers are serum eosinophilic cationic pro-
tein (ECP), induced sputum cellularity and soluble mark-
ers [6], and the concentration of nitric oxide in exhaled air
(FENO) [7, 8].
Eosinophil protein X (EPX) is one of the toxic pro-
teins present in eosinophil granules and is released by acti-
vated eosinophils. EPX can be measured accurately in urine
(uEPX) [9]. Therefore, uEPX can be regarded as a marker of
eosinophil degranulation in vivo [10]. uEPX levels in allergic
asthmatic children were found to be significantly higher than
in healthy controls [11–14]. Treatment with inhaled steroids
reduced uEPX levels [14]. We hypothesized that measuring
EPX in urine could potentially prove to be useful for moni-
toring eosinophilic airway inflammation in children andmay
complement other markers of asthma control such as symp-
tom scores and lung function
The aim of this study was to evaluate the relationship be-
tween uEPX and current symptoms and lung function pa-
rameters, and the relation between uEPX, induced sputum
eosinophilia, and FENO. For this purpose, we analyzed cross-
sectional data obtained at enrolment for a multicentre trial.
2. METHODS
2.1. Subjects
Data were obtained from steroid-dependent asthmatic chil-
dren who took part in a large randomized controlled mul-
ticentre trial (CATO: Children Asthma Therapy Optimal).
One hundred and eighty atopic (RAST ≥ class 1 for at
least one airborne allergen) children, median age 10.3 years
(range 6–16 years), with a documented clinical history of
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moderately severe asthma were recruited from paediatric
clinics in 8 general hospitals and 7 university hospitals in
The Netherlands. All had been treated with inhaled corticos-
teroids (ICS) for at least 4 weeks. Data were obtained during
a clinic visit at the end of the run in period of 4–12 weeks.
During this period, they were treated with fluticasone dipro-
pionate 200μg/d (n = 102 ) or 500μg/d (n = 78). All par-
ents and children if > 12 years gave their written informed
consent. The study was approved by the medical ethics com-
mittees of all participating hospitals.
2.2. Symptom scores
Two weeks before visiting the hospital, patients kept a diary
in which symptoms (shortness of breath, wheeze, and cough)
were scored twice a day each on a 4-point (0–3) scale. Cu-
mulative symptom scores were calculated over 14 days (max-
imum score 252).
2.3. Fractional exhaled nitric oxide
The fractional concentration of exhaled nitric oxide (FENO)
was measured with the online single breath method, using
the NIOX NO-analyzer (Aerocrine, Stockholm, Sweden) ac-
cording to ERS/ATS guidelines [15].
As FENO could only be measured in 1 participating uni-
versity centre, only part of the children underwent FENO
measurements.
2.4. Flow-volume curves
Flow-volume curves and forced expiratory volume in 1 sec-
ond (FEV1) were measured on a dry rolling seal spirometer
according to recommendations [16]. Results are expressed as
percentage of predicted values [17].
2.5. Bronchial challenge test
Bronchial responsiveness was determined by a methacholine
challenge [18]. PD20 methacholine (provocative dose of
methacholine causing FEV1 fall 20% from baseline) was as-
sessed by linear interpolation of the last two points of the
log dose-response curve where FEV1 had fallen below 20%
of baseline value.
2.6. Sputum induction and processing
Sputum induction was performed by 5 university centres
and 3 paediatric clinics in general hospitals. Sputum was in-
duced according to a standardized method by inhaling an
aerosol prepared from hypertonic sodium chloride 4.5% w/v
[19, 20]. Differential cell counts of the cytospins were per-
formed by counting 500 cells. Sputum samples containing
more than 80% squamous cells were excluded from the anal-
ysis [20].
In sputum supernatant, ECP was measured by fluoroen-
zyme immunoassay (Pharmacia, Uppsala, Sweden)
2.7. Urinary eosinophil protein X
A spot sample urine was collected from each individual
at the clinic visit and immediately stored at −20◦C. uEPX
was determined using a commercial enzyme-linked im-
munosorbent assay (ELISA) for human EPX in 50-fold
diluted samples according to the manufacturers recom-
mendations (Medical and Biological Laboratories, Naka-Ku
Nagoya, Japan). The sensitivity of the assay was 0.62ng/mL.
Urinary creatinine levels were measured by using the alka-
line picrate method (Jaffe´ reaction) (Roche, Mannheim, Ger-
many). Urinary EPX concentrations were expressed as μg per
mmol creatinine (uEPX/c).
2.8. Data analysis
All variables with a non-Gaussian distribution (symptom
score, PD20 methacholine, FENO, % eosinophils in sputum,
ECP in sputum, and uEPX) could be normalized by log-
transformation. The significance of the relation between
uEPX and lung function variables or other markers of in-
flammation was calculated using Spearman’s rank correla-
tion coefficients. A two-sided P value of <.05 was considered
statistically significant.
3. RESULTS
One hundred and eighty subjects (105 boys (58.3%)) par-
ticipated. Asthma was controlled by fluticasone dipropionate
200μg/day (n = 102) or 500μg/day (n = 78).
All subjects performed spirometry and recorded symp-
toms in a diary. Six children inhaled short-acting β-agonists
prior to the visit, their results were excluded from analy-
sis. One hundred and seventy eight children performed a
bronchial challenge test; two had FEV1 < 80% of personal
best and were therefore not tested. Children who had used
β-agonist within 8 hours before the test (n = 6) were again
excluded. For logistic reasons, sputum induction was done in
part of the subjects. Forty nine of the 98 sputum inductions
yielded adequate sputum samples (50%). At randomization,
only one university centre had the facility to measure FENO
(n = 24 subjects).
Baseline results of lung function, symptom score, and
markers of inflammation are given in Table 1. uEPX/c
showed a log-normal distribution, median 185μg/mmol cre-
atinine (range 2–3114μg/mmol creatinine). UEPX/c did not
correlate with age and was not different between boys and
girls.
3.1. Relation between uEPX/c and clinical markers of
asthma severity (Table 2)
UEPX/c did not correlate with symptom scores or inhaled
steroid dose. There was a significant inverse correlation of
uEPX/c with FEV1(r = −.18 , P = .02) (Figure 1). The asso-
ciation between uEPX/c and FEV1 did not significantly differ
between children using 200μg fluticasone per day and those
using 500μg (Anova, P = .19). For each 10% points increase
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Table 1: Characteristics of study subjects. Values are median (range). FEV1 is forced expiratory volume in 1 second; PD20 methacholine is
provocative dose of methacholine causing FEV1 fall 20% from baseline; ECP is eosinophil cationic protein; FENO is fractional concentration
of nitric oxide in exhaled air; uEPX/c is urinary eosinophil protein X per mmol creatinine.
Fluticasone dose Total
200μg/day 500μg/day –
Age (years) 10(96.4− 16.8) 11.3(6.4− 16.7) 10.3(6.4− 16.8)
n = 102 n = 78 n = 180
Gender (m/f) 60/40 45/33 105/75
FEV1 (pred. %) 99(56− 135) 96(56− 96) 97(56− 135)
n = 101 n = 73 n = 174
Cumulative symptom score 18.5(0− 113) 14(0− 152) 17.0(0− 152)
n = 102 n = 78 n = 180
PD20 methacholine (μg) 200(3− > 1570) 48(1− > 1570) 68(1− > 1570)
n = 100 n = 72 n = 172
Eosinophils sputum (%) 1(0− 72) 1(0− 43) 1.0(0− 72)
n = 29 n = 20 n = 49
ECP sputum (ng/ml) 17(0− 2345) 38(0− 538) 29(0− 2345)
n = 24 n = 19 n = 43
FENO (ppb) 11(5− 63) 9(1− 29) 10(1− 63)
n = 12 n = 12 n = 24
uEPX/c (μg/mmol) 189(2− 2828) 180(10− 3114) 185(2− 3114)
n = 102 n = 78 n = 180
Table 2: Correlations between uEPX or uEPX-c and clinical markers of asthma severity or markers of asthmatic inflammation. r values were
all analyzed by Spearman’s rank correlation tests. uEPX/c is urinary eosinophil protein X per mmol creatinine; FEV1 is forced expiratory
volume in 1 second; PD20 methacholine is provocative dose of methacholine causing FEV1 fall 20% from baseline; ECP is eosinophil cationic
protein; FENO is fractional concentration of nitric oxide in exhaled air.
Variable N
Log uEPX/c
r P
Age 180 −.01 .90
Symptom score 180 .03 .72
FEV1 174 −.18 .02
PD20 methacholine 172 −.14 .08
% eosinophils in sputum 49 .17 .26
ECP sputum 43 −.03 .83
FENO 24 .16 .46
of FEV1 (pred. %) the geometric mean EPX/c ratio decreases
18% (95% CI: 5,30%). The correlation between uEPX/c and
PD20 methacholine was borderline significant (r = −.14,
P = .08).
3.2. Relation between uEPX and markers of asthmatic
airway inflammation (Table 2)
uEPX/c did not correlate with the % eosinophils or ECP in
induced sputum, or with FENO. Relations between uEPX and
PD20 methacholine or markers of asthmatic airway inflam-
mation did not significantly differ when analysis was adjusted
for fluticasone dose.
Correlations were similar when children with eczema
were excluded from the analysis.
4. DISCUSSION
We found a significant correlation of uEPX/c and FEV1, and
no association between uEPX/c and bronchial responsiveness
or symptom scores in a large group of children with moder-
ately severe allergic asthma. In subgroups, no significant cor-
relations between uEPX/c and other markers of eosinophilic
airways inflammation (% eosinophils and ECP in induced
sputum or FENO) were found.
This is the first study reporting uEPX/c levels in rela-
tion with markers of asthma severity and inflammation in a
large population of children with atopic asthma, treated with
inhaled steroids. Lugosi et al. have shown that uEPX levels
were increased in symptomatic versus nonsymptomatic chil-
dren with asthma, treated with inhaled steroids or disodium
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Figure 1: Scatter plot of urinary eosinophil protein X per mmol
creatinine (uEPX-c) versus forced expiratory volume in 1 second
(FEV1), n = 174.
cromoglycate [21], and Oosaki et al. [22] found significantly
elevated uEPX levels during acute asthma exacerbationss in
children. All subjects included in our study had stable well-
controlled asthma, as evidenced by a median cumulative
symptom score of only 17 of a maximum of 252. Conflict-
ing data have been published on the association between
uEPX/c and pulmonary function tests [21, 23]. We found a
significant negative correlation between FEV1 and uEPX/c.
It should be mentioned that the scatter was wide, and in-
dividual uEPX/c therefore varied widely for a given FEV1
level. Hence, such correlations are unlikely to be detected
in smaller groups. However, the within-subject variation of
both parameters in time had not been studied. We con-
firmed our hypothesis that uEPX/c and bronchial hyperre-
sponsiveness are not closely correlated. Lack of correlation
between the severity of bronchial hyperresponsiveness and
uEPX/c levels was also reported in 3 previous studies [24–
26]. A close correlation between bronchial hyperresponsive-
ness and uEPX/c was not expected, because bronchial hy-
perresponsiveness is multifactorial and is not only caused by
(eosinophilic) airways inflammation, but also by airway ge-
ometry, airway remodelling, and autonomic dysregulation.
Our hypothesis that uEPX/c would correlate with mark-
ers of eosinophilic airway inflammation could not be con-
firmed, as we found no correlation between uEPX/c and the
percentage eosinophils in induced sputum. Others likewise
found no correlation between uEPX/c and bronchoalveolar
lavage cell counts in adult asthmatic patients [10]. An al-
ternative explanation for not finding significant correlations
between percentages of sputum eosinophils and uEPX/c
could be that uEPX is only released by activated eosinophils,
whereas in sputum we counted activated as well as nonacti-
vated eosinophils. Also, the number of children from whom
suitable sputum samples or FENO values were obtained was
relatively small.
We found no correlation between uEPX/c and sputum
ECP levels. In contrast, Mattes et al. [11] reported a pos-
itive correlation between uEPX/c and sputum ECP in 25
stable asthmatic children on inhaled corticosteroids. They
found much higher ECP concentrations than we did (me-
dian 453ng/mL, range 40–2600; and 29ng/ml, 1-2345, resp.).
The reason for this is not clear, but may be related to different
sputum processing techniques.
One could argue that the lack of correlation between
uEPX/c and percentage of sputum eosinophils, or ECP levels
in sputum supernatant, could be due to the wide scatter of
uEPX. However, all urine samples were immediately stored
at −20◦C and uEPX and urinary creatinine levels measure-
ments were performed in a central laboratory (Leiden Uni-
versity Medical Hospital) to reduce variability in the analy-
sis. All EPX measurements were done in duplicate and the
within-subject reproducibility of uEPX levels was good.
It has been reported that in atopic dermatitis, concen-
trations of eosinophil- specific mediators, including uEPX/c,
are increased [27, 28]. However, we found that the presence
or absence of atopic eczema did not influence the correla-
tions between uEPX/c and the percentage eosinophils or ECP
in induced sputum. We cannot exclude that heterogeneity
of study groups with respect to other atopic disorders than
asthma could have affected the correlation between uEPX/c
and other markers of eosinophilic airways inflammation.
At the onset of our study, a circadian rhythm of uEPX/c
had not been reported. Urine samples were not all obtained
at the same time of the day. Since the start of our study, it be-
came evident that a circadian rhythm of uEPX/c with lowest
levels at 7 p.m. and highest at 7 a.m. in both asthmatic and
healthy controls exists [23, 29–31]. Hence, diurnal variabil-
ity may have introduced scatter of uEPX, thus weakening a
possible correlation.
Two previous studies reported significant positive cor-
relations between uEPX/c and FENO in corticosteroid-
dependent childhood asthma [11, 29]. We found no signif-
icant correlation between uEPX/c and FENO in a small sub-
group of the study population. For FENO, no important cir-
cadian variation was found, employing the same measure-
ment technique that we have used [32], but conflicting re-
sults have also been published [27, 33]. A possible circadian
rhythm might have affected FENO and weakened any cross-
sectional relationship.
In conclusion, the present data show a weak inverse cor-
relation between uEPX/c and FEV1, and a borderline corre-
lation between uEPX/c and PD20 methacholine. No signifi-
cant correlation was found between uEPX/c and markers of
eosinophilic airway inflammation including % eosinophils
or ECP levels in induced sputum or FENO. The number of
children performing FENO was small, therefore this correla-
tion should be interpreted with caution. Our findings are not
encouraging for uEPX/c as a complementary marker of air-
way inflammation in asthma. As to whether uEPX/c can be
useful as a marker for monitoring asthma management in
children is worth prospectively looking at.
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